The Experts below are selected from a list of 51 Experts worldwide ranked by ideXlab platform
Ronald A. Simon - One of the best experts on this subject based on the ideXlab platform.
-
Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs
Current Allergy and Asthma Reports, 2004Co-Authors: Ronald A. SimonAbstract:Aspirin-exacerbated respiratory disease (AERD) is an adultonset condition that manifests as asthma, rhinosinusitis/nasal polyps, and sensitivity to aspirin and other cyclooxygenase-1 (COX-1)-inhibitor nonsteroidal anti-inflammatory drugs (NSAIDs). There is no cross-sensitivity to highly selective COX-2 inhibitors. AERD is chronic and does not improve with avoidance of COX-1 inhibitors. The diagnosis of AERD is made through provocative challenge testing. Following a positive aspirin challenge, patients can be desensitized to aspirin and NSAIDs. The desensitized state can be maintained indefinitely with continued daily administration. After desensitization, there is an approximately 48-hour refractory period to adverse effects from aspirin. The pathogenesis of AERD remains unknown, but these patients have been shown to have multiple abnormalities in arachidonic acid metabolism and in cysteinyl leukotriene 1 receptors. AERD patients can take up to 650 mg of acetaminophen for analgesic or antipyretic relief. Patients can also use weak COX-1 inhibitors, such as sodium salicylate or Choline Magnesium Trisalicylate. Treatment of AERD patients with antileukotriene medications has been helpful but not preferential when compared with non-AERD patients. An alternative treatment for many AERD patients is aspirin desensitization. This is particularly effective in reducing upper-airway mucosal congestion, nasal polyp formation, and systemic steroids.
D. C. Brater - One of the best experts on this subject based on the ideXlab platform.
-
The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis
European Journal of Clinical Pharmacology, 1992Co-Authors: T. S. Tracy, K. Krohn, D. R. Jones, J. D. Bradley, S. D. Hall, D. C. BraterAbstract:We have studied the pharmacokinetics of methotrexate in patients with rheumatoid arthritis concurrently treated with Choline Magnesium Trisalicylate, ibuprofen, naproxen, or a non-NSAID analgesic (control treatment). The apparent systemic clearance of methotrexate was significantly reduced by all three treatments. Trisalicylate and ibuprofen both significantly reduced methotrexate renal clearance, but only the Trisalicylate significantly displaced methotrexate from protein, increasing the fraction unbound by 28%. These data show that NSAIDs can affect the disposition of methotrexate, possibly increasing the potential for toxicity and necessitating dosage adjustments. However, large inter-subject variability precludes specific dosage recommendations.
T. S. Tracy - One of the best experts on this subject based on the ideXlab platform.
-
The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis
European Journal of Clinical Pharmacology, 1992Co-Authors: T. S. Tracy, K. Krohn, D. R. Jones, J. D. Bradley, S. D. Hall, D. C. BraterAbstract:We have studied the pharmacokinetics of methotrexate in patients with rheumatoid arthritis concurrently treated with Choline Magnesium Trisalicylate, ibuprofen, naproxen, or a non-NSAID analgesic (control treatment). The apparent systemic clearance of methotrexate was significantly reduced by all three treatments. Trisalicylate and ibuprofen both significantly reduced methotrexate renal clearance, but only the Trisalicylate significantly displaced methotrexate from protein, increasing the fraction unbound by 28%. These data show that NSAIDs can affect the disposition of methotrexate, possibly increasing the potential for toxicity and necessitating dosage adjustments. However, large inter-subject variability precludes specific dosage recommendations.
V Wright - One of the best experts on this subject based on the ideXlab platform.
-
a comparison of Choline Magnesium Trisalicylate and acetylsalicylic acid in patients with rheumatoid arthritis
Current Medical Research and Opinion, 1990Co-Authors: Le P Gallez, H A Bird, V WrightAbstract:SummaryCholine Magnesium Trisalicylate (3.0 g/day) and enteric-coated acetylsalicylic acid (3.0 g/day) have been compared in a double-blind, crossover study on 19 patients with rheumatoid arthritis using the double-dummy technique. Patients were allocated to receive 3-weeks' treatment with each trial drug in random sequence and were assessed at Weeks -1, 0, 3 and 6. Apart from an unexplained significant improvement in grip strength (p<0.01) that occurred in patients on Choline Magnesium Trisalicylate when this followed aspirin but not when it preceded it, there was no significant clinical difference between treatments in any of the clinical parameters of improvement that were measured. There was also no clear difference in the side-effects profile produced by the two drugs, but the number of patients recruited to this study was small.
-
A comparison of Choline Magnesium Trisalicylate and acetylsalicylic acid in patients with rheumatoid arthritis.
Current Medical Research and Opinion, 1990Co-Authors: P. Le Gallez, Howard Bird, V WrightAbstract:SummaryCholine Magnesium Trisalicylate (3.0 g/day) and enteric-coated acetylsalicylic acid (3.0 g/day) have been compared in a double-blind, crossover study on 19 patients with rheumatoid arthritis using the double-dummy technique. Patients were allocated to receive 3-weeks' treatment with each trial drug in random sequence and were assessed at Weeks -1, 0, 3 and 6. Apart from an unexplained significant improvement in grip strength (p
K. Krohn - One of the best experts on this subject based on the ideXlab platform.
-
The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis
European Journal of Clinical Pharmacology, 1992Co-Authors: T. S. Tracy, K. Krohn, D. R. Jones, J. D. Bradley, S. D. Hall, D. C. BraterAbstract:We have studied the pharmacokinetics of methotrexate in patients with rheumatoid arthritis concurrently treated with Choline Magnesium Trisalicylate, ibuprofen, naproxen, or a non-NSAID analgesic (control treatment). The apparent systemic clearance of methotrexate was significantly reduced by all three treatments. Trisalicylate and ibuprofen both significantly reduced methotrexate renal clearance, but only the Trisalicylate significantly displaced methotrexate from protein, increasing the fraction unbound by 28%. These data show that NSAIDs can affect the disposition of methotrexate, possibly increasing the potential for toxicity and necessitating dosage adjustments. However, large inter-subject variability precludes specific dosage recommendations.